Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPivotal Data Demonstrating Efficacy of Darusentan in Treating Resistant Hypertension Published in The Lancet
Gilead, 09/14/09
Gilead Sciences, Inc. announced the publication of data from DAR–311 (DORADO), a Phase III clinical trial evaluating the company’s once–daily oral endothelin receptor antagonist darusentan as an add–on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three drug antihypertensive regimen that includes a diuretic.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor